Online inquiry

IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6031MR)

This product GTTS-WQ6031MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6031MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7599MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11101MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ7124MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ14629MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ10109MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ15854MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ10696MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ8473MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW